Clinical Trials at Advocate Lutheran General Hospital

As of July 2026, 58 paid clinical trials are recruiting at Advocate Lutheran General Hospital, located at 1775 DEMPSTER ST, PARK RIDGE, IL 60068-1143, phone (847) 723-7313 in Park Ridge, Illinois. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

58 clinical trials at Advocate Lutheran General Hospital

·Clear filters·↓ Download CSV

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

336 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Drug: Nivolumab

392 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting

Apply to this trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for Advanced Esophageal Adenocarcinoma

Drug: Nivolumab

373 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06203600·Phase 2, Phase 3·Recruiting

Apply to this trial

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for Metastatic Clear Cell Renal Cell Carcinoma

387 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04510597·Phase 3·Recruiting

Apply to this trial

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

for Head and Neck Squamous Cell Carcinoma

200 locations incl. Gilbert

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06992427·Phase 3·Recruiting

Apply to this trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for Renal Pelvis and Ureter Urothelial Carcinoma

Drug: Durvalumab

258 locations incl. Kingman

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04628767·Phase 2, Phase 3·Recruiting

Apply to this trial

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

for Recurrent Endometrial Carcinoma

Drug: Selumetinib

293 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05554328·Phase 2·Recruiting

Apply to this trial

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

for Advanced Colorectal Carcinoma

225 locations incl. Fort Smith

Sponsor: University of Rochester

Sex: All·Age: 18+

Code: NCT06073431·Recruiting

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for Prostate Adenocarcinoma

402 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT05946213·Phase 3·Recruiting

Apply to this trial

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

for Metastatic Head and Neck Squamous Cell Carcinoma

177 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06589804·Phase 3·Recruiting

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

for Lung Non-Small Cell Carcinoma

248 locations incl. Jonesboro

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06116682·Phase 2·Recruiting

Apply to this trial

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

for Metastatic Dedifferentiated Liposarcoma

246 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06422806·Phase 3·Recruiting

Apply to this trial

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

for Non Small Cell Lung Cancer

Drug: Osimertinib

146 locations incl. Birmingham

Sponsor: PrECOG, LLC.

Sex: All·Age: 18+

Code: NCT06538038·Recruiting

Apply to this trial

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

for Hematologic Malignancies

142 locations incl. Birmingham

Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All·Age: All ages

Code: NCT01351545·Recruiting

Apply to this trial

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

for Cutaneous Melanoma, Stage II

130 locations incl. Mobile

Sponsor: Melanoma and Skin Cancer Trials Limited

Sex: All·Age: 18+

Code: NCT03860883·Recruiting

Apply to this trial

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

for Stroke

45 locations incl. Birmingham

Sponsor: University of Cincinnati

Sex: All·Age: 18+

Code: NCT05338697·Recruiting

Apply to this trial

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

for Alzheimers Disease

12 locations incl. Birmingham

Sponsor: Washington University School of Medicine

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT05552157·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

for Alzheimers Disease

12 locations incl. Birmingham

Sponsor: Washington University School of Medicine

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06647498·Phase 2, Phase 3·Recruiting

Apply to this trial